Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and amendment tied to its March 2024 acquisition of AlmataBio, Inc. The original $15 million contingent milestone payment, due upon dosing the first patient in a Phase 3 trial, has been restructured.
Avalo will pay $2.25 million to the former AlmataBio securityholders within five business days of April 26, 2026 and gains an option, exercisable within 90 days, to pay an additional $5.125 million in cash, common stock, or both, in full satisfaction of the milestone. If Avalo does not exercise this option, it would instead owe $12.75 million in cash or stock upon achievement of the Phase 3 dosing milestone.
Avalo Therapeutics, Inc. is holding a virtual 2026 Annual Meeting of Stockholders on June 2, 2026, for holders of 26,714,337 common shares as of April 6, 2026. Stockholders will vote on electing seven directors, approving a Second Amended and Restated 2016 Employee Stock Purchase Plan, and ratifying Ernst & Young LLP as independent auditor for 2026.
The updated employee stock purchase plan would keep 961,608 shares available and add an annual “evergreen” increase from 2027 through 2036, capped at the lesser of 1% of specified equity outstanding or 4,000,000 shares per year. The proxy also outlines Avalo’s board independence, committee structure, director compensation, and governance policies.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, Doyle exercised options to acquire 3,970 shares of common stock at $12.65 per share, then sold all 3,970 shares in open-market trades at an average price of about $18.01, with individual trades ranging from $18.00 to $18.10. Following the sale, Doyle directly held 3,622 shares of common stock and 210,530 stock options. The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, and that the underlying option vests over four years, with 25% vesting on July 15, 2025 and the remainder in equal monthly installments over the next three years.
AVTX filed a Form 144 disclosing the proposed sale of 65,800 shares of common stock on 04/06/2026 arising from an exercise of stock options for cash. The filing also lists recent Rule 10b5-1 sales by Mittie Doyle: 25,492 shares on 03/16/2026 and 679 shares on 04/01/2026.
Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported open-market sales of Avalo common stock in early April 2026. He sold a total of 15,959 shares over two days at prices around $15.858 to $17.5674 per share, in multiple transactions.
The filing notes these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following the transactions, Sullivan directly holds 17,338 shares of Avalo Therapeutics common stock.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an option exercise and same-day share sale in Avalo Therapeutics, Inc. common stock. Mittie exercised stock options to acquire 679 shares of common stock at $8.04 per share, then sold 679 shares at $16.00 per share in an open-market transaction.
After these transactions, Mittie directly holds 3,622 shares of common stock and 148,329 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the timing was set in advance rather than decided on the trade date.
Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.
Avalo Therapeutics director Kevin Robert Lind received a grant of stock options as part of his compensation. On March 31, 2026, he was awarded options to purchase 1,370 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The filing notes these options were granted on March 31, 2026 and are 100% vested, meaning they are fully exercisable immediately. After this grant, Lind holds options covering 1,370 shares, which expire on March 31, 2036 if not exercised.